News Headlines

  1. Synthego And Vita Therapeutics Announce Strategic Licensing Agreement For hfCas12Max CRISPR Nuclease 4/8/2025

    Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into Vita's cell therapeutic programs.

  2. BDD Pharma Opens Brand New GMP Manufacturing Facility Following £2M In Funding 4/8/2025

    Leading contract research company BDD has opened its new 122m² GMP manufacturing facility at BioCity near Glasgow, following a successful inspection by the Medicines and Healthcare products Regulatory Authority (MHRA) in March 2025.

  3. Asahi Kasei Establishes Asahi Kasei Life Science To Drive Its Bioprocess Businesses Forward 4/8/2025

    To meet growing demand from the pharmaceutical industry, Asahi Kasei has established Asahi Kasei Life Science to operate its bioprocess businesses under a new organizational structure.

  4. Gift Of Life Biologics And Cellex Cell Professionals GmbH Celebrate Successful Partnership To Deliver High-Quality Starting Materials For Final Drug Product Manufacturing In Cell And Gene Therapy 4/7/2025

    Gift of Life Biologics, a leading supplier of high-quality cellular starting materials in the US, and Cellex Cell Professionals, a trusted Contract Development and Manufacturing Organization (CDMO) with 10+ years' experience in cell and gene therapy (CGT), are pleased to announce the continued success of their collaboration that has been ongoing since 2022.

  5. AGC Biologics Strengthens Single-Use Technology Network, Adds 5,000 L Vessels From Thermo Scientific To New Yokohama, Japan Facility 4/7/2025

    Today, we announced a strategic decision about the large-scale single-use technology it will use at its new Yokohama, Japan facility.

  6. Ethris And Lonza Collaborate To Develop Spray-Dried mRNA Vaccines For Respiratory Disease Prevention 4/7/2025

    Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal delivery that offer a promising approach to combat respiratory diseases.

  7. ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement With GSK To Develop Novel Medicines For Neurodegenerative Diseases 4/6/2025

    ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B.

  8. INCOG Biopharma Services Announces Significant 2025 Expansion Efforts, Celebrates 2024 Milestones 4/3/2025

    INCOG BioPharma Services, a leading contract development and manufacturing organization (CDMO) specializing in sterile injectable biopharmaceuticals, has announced strategic expansion projects for 2025. These efforts include the physical expansion of their Fishers-based facilities, scaling up of core filling capabilities, adding significant new finishing capabilities, and strategic hiring focused on attracting top-tier talent.

  9. TopGum Closes Acquisition Of Island Abbey Nutritionals 4/3/2025

    Gummy supplement specialist TopGum Industries, Ltd. (TASE: TPGM), announced today that it has completed the acquisition of Island Abbey Nutritionals™, a leading CDMO specializing in supplement gummies and lozenges, located in Prince Edward Island, Canada.

  10. HALiXPEDITE: Transforming Biologics Therapy Development Programs With Seamless R&D To GMP Integration 4/3/2025

    HALIX, a leading global healthcare Contract Development and Manufacturing Organization (CDMO), introduces HALiXPEDITE at the Innovation for Health conference in Rotterdam.